Lead Product(s) : Parathyroid Hormone
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Takeda Provides NATPARA Regulatory Update
Details : The CRL indicates that the FDA has completed its review of the NATPARA, is a prescription parathyroid hormone PAS and determined that it cannot be approved in its present form.
Product Name : Natpara
Product Type : Peptide
Upfront Cash : Inapplicable
March 22, 2022
Lead Product(s) : Parathyroid Hormone
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
